Invention Grant
US09309515B2 Aptamer which selectively binds to ERBB2 receptor and uses thereof
有权
选择性结合ERBB2受体的适配体及其用途
- Patent Title: Aptamer which selectively binds to ERBB2 receptor and uses thereof
- Patent Title (中): 选择性结合ERBB2受体的适配体及其用途
-
Application No.: US14128152Application Date: 2011-08-10
-
Publication No.: US09309515B2Publication Date: 2016-04-12
- Inventor: Jung Hwan Lee , Young Chan Chae , Youngdong Kim , Hyungu Kang , Jong Hun Im , Jong In Kim , Ki Seok Kim , Sung Key Jang , Il Ung Oh , Min Jeong Choi , Won Jun Kang
- Applicant: Jung Hwan Lee , Young Chan Chae , Youngdong Kim , Hyungu Kang , Jong Hun Im , Jong In Kim , Ki Seok Kim , Sung Key Jang , Il Ung Oh , Min Jeong Choi , Won Jun Kang
- Applicant Address: KR Pohang KR Cheongwon-Gun
- Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION,KOREA FOOD & DRUG ADMINISTRATION
- Current Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION,KOREA FOOD & DRUG ADMINISTRATION
- Current Assignee Address: KR Pohang KR Cheongwon-Gun
- Agency: Lex IP Meister, PLLC
- Priority: KR10-2011-0061939 20110624
- International Application: PCT/KR2011/005852 WO 20110810
- International Announcement: WO2012/176952 WO 20121227
- Main IPC: C12N15/11
- IPC: C12N15/11 ; C12N15/115 ; A61K31/7088 ; G01N33/574 ; A61K47/48
Abstract:
Disclosed are a DNA aptamer specifically binding to the Her2 (ERBB2) receptor involved in the onset of breast cancer, a composition for the suppression of cancer metastasis comprising the same as an active ingredient, and a composition for the diagnosis of cancer comprising the same as an active ingredient. Due to its binding mechanism being different from that of the conventional antibody, the aptamer can be effectively used for suppressing cancer metastasis and diagnosing cancer.
Public/Granted literature
- US20150005368A1 APTAMER WHICH SELECTIVELY BINDS TO ERBB2 RECEPTOR AND USES THEREOF Public/Granted day:2015-01-01
Information query
IPC分类:
